SUPPORT EAP TO FACILITATE THE USE OF HUMAN CONVALESCENT PLASMA TO TREAT HOSPITALIZED CORONAVIRUS-2 (SARS-COV-2) COVID-19 PATIENTS

  • Funded by Biomedical Advanced Research and Development Authority (BARDA)
  • Total publications:11 publications

Grant number: 75A50120C00096

Award search

Key facts

  • Disease

    COVID-19
  • Start & end year

    2020
    2022
  • Known Financial Commitments (USD)

    $48,927,887
  • Funder

    Biomedical Advanced Research and Development Authority (BARDA)
  • Research Location

    United States of America
  • Lead Research Institution

    MAYO CLINIC
  • Research Priority Alignment

    N/A
  • Research Category

    Clinical characterisation and management
  • Research Subcategory

    Supportive care, processes of care and management
  • Special Interest Tags

    N/A
  • Study Type

    Clinical
  • Clinical Trial Details

    Not applicable
  • Broad Policy Alignment

    Pending
  • Age Group

    Unspecified
  • Vulnerable Population

    Unspecified
  • Occupations of Interest

    Unspecified

Abstract

SUPPORT EAP TO FACILITATE THE USE OF HUMAN CONVALESCENT PLASMA TO TREAT HOSPITALIZED CORONAVIRUS-2 (SARS-COV-2) COVID-19 PATIENTS

11 Publications linked via Europe PMC

Cardiac troponin T elevation predicts mortality in hospitalized COVID-19 patients.

Access to and safety of COVID-19 convalescent plasma in the United States Expanded Access Program: A national registry study.

Early but not late convalescent plasma is associated with better survival in moderate-to-severe COVID-19.

Convalescent plasma use in the USA was inversely correlated with COVID-19 mortality.

The Principles of Antibody Therapy for Infectious Diseases with Relevance for COVID-19.

Convalescent Plasma Antibody Levels and the Risk of Death from Covid-19.

Treatment of severe COVID-19 with convalescent plasma in Bronx, NYC.

The Assessment of Convalescent Plasma Efficacy against COVID-19.

Safety Update: COVID-19 Convalescent Plasma in 20,000 Hospitalized Patients.